Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2021

NEXT STORY
Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers
PREV STORY
Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology

author_avatar
NASDAQ Market News

PAVmed Subsidiary Lucid Diagnostics Launches World-Class Medical Advisory Board and Appoints Chief Medical Officer

author_avatar
NASDAQ Market News

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

author_avatar
NASDAQ Market News